Phase 2b study of Empatic for weight loss - MPR

Links shared publicly online about this topic.

1,711
total visits

Phase 2b study of Empatic for weight loss - MPR

Orexigen Therapeutics announced positive results from its Phase 2b trial for Empatic (bupropion SR/zonisamide SR), its investigational combination drug for the treatment of obesity.

View full resource at empr.com

Tags: Antidepressant, Weight Loss, Drug, Smoking Cessation Medication, Wellbutrin, Zyban, News

Most Recently Shared on September 30, 2009 at 5:24 pm By:

MPR

MPR News: Phase 2b study of Empatic for weight loss: Orexigen Therapeutics announced positive results .. http://bit.ly/vfz9V

3 years ago...

Retweet

Favorite

Orexigen's Empatic Phase 2b results demonstrate weight loss

news-medical.net — “Orexigen Therapeutics, Inc. today announced that its 24-week, Phase 2b trial for Empatic(TM) (bupropion SR/zonisamide SR), the Company's second late stage investigational combination drug for the treatment of obesity, met its primary efficacy endpoint by demonstrating statistically significantly greater weight loss for both Empatic doses compared to monotherapies and placebo.” View full resource at news-medical.net